Compare IIIV & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | BDSX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.5M | 276.2M |
| IPO Year | 2018 | 2020 |
| Metric | IIIV | BDSX |
|---|---|---|
| Price | $18.98 | $9.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $25.50 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 283.3K | 69.7K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | $2.13 | $26.35 |
| Revenue Next Year | $4.98 | $20.40 |
| P/E Ratio | $79.25 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $13.63 | $5.26 |
| 52 Week High | $30.09 | $31.97 |
| Indicator | IIIV | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 18.08 |
| Support Level | $18.47 | N/A |
| Resistance Level | $23.29 | $16.66 |
| Average True Range (ATR) | 0.60 | 2.10 |
| MACD | 0.20 | -0.96 |
| Stochastic Oscillator | 79.65 | 3.74 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.